The increasing prevalence of multiple sclerosis (MS) advancements in neurostimulation and wearable are driving the growth of the Multiple Sclerosis Treatment Devices Market at a CAGR of 5.08% during the forecast period 2025 to 2035

Market Research Future (MRFR) has published a cooked research report on the “Global Multiple Sclerosis Treatment Devices Market” that contains the information from 2019 to 2035.

The Global Multiple Sclerosis Treatment Devices Market is estimated to register a CAGR of 5.08 % during the forecast period of 2025 to 2035.

MRFR recognizes the following companies as the key players in the Global Multiple Sclerosis Treatment Devices Market — Enovis, Axonics, Inc., Koninklijke Philips N.V., BTL, Bayer AG, Medtronic, Abbott, Boston Scientific Corporation, Biotronik, Saluda Medical Pty Ltd and others.

The Global Multiple Sclerosis Treatment Devices Market accounted for registering a CAGR of 5.08 % during the forecast period and is estimated to reach USD 1.46 Billion by 2035.

The rising prevalence of Multiple Sclerosis (MS) worldwide is a key factor driving the demand for MS treatment devices. MS, a chronic autoimmune disease affecting the Central Nervous System (CNS), has seen a significant increase in diagnosed cases over the past few decades. According to the Atlas of MS 2023, published by the Multiple Sclerosis International Federation (MSIF), an estimated 2.9 million people globally were living with MS, up from 2.3 million in 2013, reflecting a rising burden on healthcare systems. The prevalence and incidence of MS vary across regions, with North America and Europe having the highest rates. Canada reports approximately 288 cases per 100,000 people, making it one of the most affected countries, while in the United States, it is estimated that nearly one million people are living with MS. In Europe, Northern countries such as Norway, Sweden, and the UK report prevalence rates of 150–200 cases per 100,000 people. 

The disease is significantly more common in women, with a female-to-male ratio of nearly 3:1, further influencing market trends as gender-specific treatment approaches gain traction. The increasing prevalence of MS is fueling demand for advanced treatment solutions, including neurostimulation devices, wearable rehabilitation technologies, and others, which help manage symptoms such as spasticity, gait disorders, and chronic pain. Additionally, improved diagnostic capabilities due to advancements in imaging techniques like MRI-based lesion tracking and biomarker research are leading to earlier and more accurate diagnoses, further driving the adoption of treatment devices. The rising global MS burden has also led to increased healthcare investments, government initiatives, and funding for innovative medical technologies, positioning the MS treatment devices market for sustained growth.

Access Full Report @ https://www.marketresearchfuture.com/reports/multiple-sclerosis-treatment-devices-market-59406

Segmental Analysis

The Global Multiple Sclerosis Treatment Devices Market has been segmented based on Type, by Treatment Devices, by End-User.

Based on Type, this segment includes Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Relapsing-remitting Multiple Sclerosis (RRMS), Clinically Isolated Syndrome (CIS). The Relapsing-remitting Multiple Sclerosis (RRMS) segment dominated the global market in 2024, while the Primary Progressive Multiple Sclerosis (PPMS) segment is projected to be the fastest–growing segment during the forecast period. However, the PPMS segment is expected to witness the fastest growth during the forecast period. This growth is attributed to increasing awareness, advancements in diagnostic techniques, and the launch of novel therapies targeting progressive forms of MS. As treatment options evolve, demand for targeted PPMS solutions is anticipated to rise significantly.

Based on Treatment Devices, this segment includes Electrical Stimulation Devices (Functional Electrical Stimulation (FES) and Transcutaneous Electrical Nerve Stimulation (TENS)), Neurostimulation Devices (Spinal Cord Stimulation (SCS) and Deep Brain Stimulation (DBS)). The Electrical Stimulation Devices segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period. These devices enhance mobility and improve quality of life for patients, which has driven their widespread acceptance in both clinical and home care settings. Furthermore, this segment is projected to be the fastest-growing during the forecast period, supported by technological advancements, increased investment in neuro-rehabilitation, and rising awareness of non-pharmacological interventions. Compared to neurostimulation devices, electrical stimulation offers a cost-effective and accessible treatment option, contributing to its rapid growth and expanding role in MS symptom management.

Based on the End-User, this segment includes Hospitals & Clinics and Ambulatory Surgical Centers. The Hospitals & Clinics segment dominated the global market in 2024, while the Ambulatory Surgical Centers segment is projected to be the fastest–growing segment during the forecast period. Hospitals and clinics serve as primary centers for diagnosis, therapy initiation, and long-term management of multiple sclerosis, driving consistent demand. However, the Ambulatory Surgical Centers (ASCs) segment is projected to be the fastest growing during the forecast period. This growth is fueled by the rising preference for minimally invasive procedures, shorter recovery times, and reduced healthcare costs associated with ASCs. Increasing patient inclination toward outpatient care and advancements in portable treatment device technologies further support the rapid expansion of this segment in the coming years.

Regional Analysis

Geographically, the Global Multiple Sclerosis Treatment Devices Market has been segmented into North America, Europe, Asia-Pacific, South America, Middle East & Africa.

Major demand factors driving the Europe market are the increasing prevalence of multiple sclerosis (MS) advancements in neurostimulation and wearable. Europe dominated the global Multiple Sclerosis (MS) Treatment Devices market due to its advanced healthcare infrastructure and rising prevalence of MS. The region benefits from strong investments in research and development, along with the growing adoption of innovative neurostimulation and wearable technologies. These advancements support more effective symptom management and improve patient quality of life, driving market growth. Government initiatives and increased awareness of early diagnosis and treatment options also contribute to Europe’s leading position.

Key Findings of the Study

• The Global Multiple Sclerosis Treatment Devices Market is expected to reach USD 1.46 Billion by 2035, at a CAGR of 5.08% during the forecast period.


• The Europe region accounted for the fastest-growing global market.


• Based on the Type, the Relapsing-remitting Multiple Sclerosis (RRMS) segment was attributed to holding the largest market in 2024.


• Enovis, Axonics, Inc., Koninklijke Philips N.V., BTL, Bayer AG, Medtronic, Abbott, Boston Scientific Corporation, Biotronik, Saluda Medical Pty Ltd are some of the players in the market.